I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

Retina World Congress 2024

-
Coming soon
11:00 AM
Duration 1hr United States
Key Clinical and Anatomical Outcomes With Faricimab▼ in Patients With nAMD: Results From the TENAYA/LUCERNE Trials
Souied E, Haug S, Amador M, Kotecha A, Margaron P, Stoilov I, Tang Y

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr United States
ELEVATUM Study Design and Rationale: A Phase 4 Trial of Faricimab▼ (VABYSMO) in Underrepresented Patients With DME
Cunningham M, Brown J, Scott A, Amador M, Chang J, Stoilov I, Meldorf M, Coney J, Gonzalez L

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr United States
Efficacy and Safety of Faricimab▼ in ALTIMETER: A Trial Exploring Biomarkers of Ang-2 Inhibition in Patients With DME
Choudhry N, Amador M, Dieckmann A, Gibson K, Glittenberg C, Kotak A, Mar F, Souverain A, Titz B, Vujosevic S, Fawzi A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr United States
Assessment of the Clinical Effects of Anti-Ang-2 With Faricimab▼ Based on Key Outcomes From the YOSEMITE/RHINE Trials in Patients With DME
Udaondu P, Kim J, Manoharan N, Amador M, Willis J,Stoilov I, Mar F, Gibson K, Souverain A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr United States
Real-World Effectiveness and Durability of Faricimab▼ in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: The FARWIDE and FARETINA studies
Borkar D, Tabano D, Ko S, Leng T, Myers R, Singh R, Talks J, Peto T, Dayal P, Downey A, James N, Chi G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr United States
IL-6 Inhibition With Vamikibart in Patients With Uveitic Macular Edema: Phase 3 MEERKAT and SANDCAT Trials
Uchiyama E

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Florida, USA
Port Delivery System with Ranibizumab (PDS) Stabilizes Retinal Nonperfusion in Patients with Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR): Results from Pagoda and Pavilion Phase 3 Trials
Emanuelli A, Campochiaro P, Wirthlin R, Gill M, Howard D, Menzes A, Malhotra V, Singh N, Latkany P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Florida, USA
Long-term Efficacy and Safety of the Port Delivery System With Ranibizumab in Patients With nAMD: Results From the Portal 5-year Subgroup Analysis
Eichenbaum D, Gune S, Singh N, Cavichini M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:38 PM
Duration 5mins United States
Real-World Clinical and Anatomical Outcomes in Patients with Neovascular Age-Related Macular Degeneration Treated with Faricimab▼: the FARETINA-AMD Study
Ali F

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:40 PM
Duration 5mins United States
Efficacy, Safety, and Durability of Faricimab▼ in Macular Edema Due to Retinal Vein Occlusion: 72-Week Results From the Phase 3 BALATON and COMINO Trials
Danzig C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar